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ABSTRACT 
P68 RNA helicase, a prototypical member of the DEAD box family of RNA helicases is important 
in many biological processes, including early organ development. However, its aberrant 
expression contributes to tumor development and progression. In this study, we show that p68 
upregulates the transcriptional expression of the growth factor receptor, PDGFRβ P68 knockdown 
in MDAMB231 and BT549 breast cancer cells significantly decreases mRNA and protein levels 
of PDGFRβ and EMT markers, resulting in decreased migration. We have previously shown that 
PDGF-BB induces p68 phosphorylation, resulting in EMT via nuclear translocation of β -catenin. 
Here, we show that p68 promotes migration in response to PDGF-BB stimulation via upregulation 
of PDGFRβ in breast cancer cells, suggesting that PDGFRβ is in turn regulated by p68 to maintain 
a positive feedback loop. Further, our study reveals the association of p68 in androgen receptor 
(AR) response via PDGFRβ. We demonstrate that p68 and PDGFRβ co-regulate AR expression 
and promote androgen-mediated proliferation in breast cancer cells, highlighting the critical role 
of p68-PDGFRβ axis in AR regulation 
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CHAPTER 1 
1.  Introduction  
1.1.  Cancer 
Cancer is uncontrollable growth of the body cells. It can start in any body part. Because of this 
uncontrolled cell growth, the normal function of that organ gets affected. Therefore, cancer is the 
name given to plethora of related diseases.  
Human body is made up of many cells. Whenever old cells die or get damage, newly divided cells 
take their place to continue the normal body function. Sometimes these cells divide without 
stopping and adapt different mutations and form the tumor. This tumor changes the natural 
integrity of the organ. It hinders the normal function of the organ. Majority of the tumors form 
solid tumor like pancreatic tumor, breast tumors etc. But leukemia, which is uncontrolled growth 
of blood cells do not form such solid tumor.    
Tumors can be classified as benign or malignant. Tumors which do not spread into or invade other 
body parts are benign tumors. But sometimes, cancer cells can spread in other body parts through 
blood or the lymphatic system as well and form tumors. At this point, these tumors are called as 
malignant. 
1.1.1.Normal cells vs cancer cells 
Although cancer cells are modified body cells, they differ from each other in many ways. Normal 
body cells divide and mature and they have very specialized structures to perform their function. 
Whereas when cancer cells divide, they do not perform normal body function. Cancer cells lack 
cell-cell contact inhibition and they divide without control to form tumor mass.  
2 
Programed cell death is the phenomenon through which body gets rid of unwanted, unhealthy cells 
through relay of signaling from surrounding tissue. Cancer cells ignore these signaling and 
continue to replicate. To support this growing tumor mass, cancer cells need continuous nutrient 
and oxygen supply. In order to get that, cancer cells secrete growth factors, like VEGF, TGFβ, and 
stimulate new blood vessels formation to support tumor growth. In this way, they not only get the 
nutrients and oxygen but also find a way to discard their waste materials. 
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1.2.  Breast cancer 
In the United States, breast cancer is a common type of cancer in women. As per CDC reports, 
every year about 245,000 cases of breast cancer are diagnosed in women and about 2,200 in men, 
in the US. Rate of getting breast cancer is maintained in last decade overall but has been increasing 
in black women and Asian and Pacific Islander women. Although death rate has been decreased 
in the last few years but still it is a second leading cause of death due to cancer in Hispanic women. 
(CDC). 
Breast cancer is highly metastatic cancer. It can metastasize to distant organs like liver, lung, bone, 
and brain. Early diagnosis has greater chance for patient’s survival. But once it metastasizes, 
chances of incurability and survival decreases. Mammography is the most common method used 
for screening and detection of occurrence of the disease. There are other methods like Magnetic 
Resonance Imaging (MRI) available for the screening, which are more sensitive (Drukteinis JS, 
2013). The risk factors for this disease includes, sex, family history, unhealthy lifestyle, aging, 
estrogen, gene mutations etc.  
Some cells in ductal region of breast area become highly proliferative, which eventually may lead 
to metastatic carcinoma. To trigger this increased proliferation, different carcinogenic factors play 
their role. To establish the tumor, surrounding microenvironment plays a significant role. It has 
been found that cancer associated macrophages can generate mutagenic inflammatory 
microenvironment. In such inflammatory microenvironment, cancer cells can escape immune 
rejection (Qian BZ, 2010). In the light of variety of mutations observed in the breast tumor, new 
subset of cells called as cancer stem cells (CSCs) have been isolated. These cells are more likely 
originated from luminal epithelial progenitor cells (Molyneux G, 2010).  These cells contribute to 
further proliferation of the tumor cells. Due to mutations in proteins of many vital signaling 
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pathways like, p53, PI3K and HIF, Notch, Hedgehog, Wnt, breast cancer cells have increased 
survival, proliferation (Valenti G, 2017). 
Based on their origin and the mutations they harness, breast cancers are categorized in different 
types like, basal like tumor with ER-, PR-, HER2- (triple negative) mutations, luminal tumor with 
ER+, PR+, Her2- mutations, HER2 tumors with ER-, PR-, HER 2 + mutations, etc. Other than ER, 
PR genes mutations, there are several other genes that have mutations closely related to breast 
cancer. For example, BRCA1 and BRCA2 (Breast cancer associated gene 1 and 2). These are anti 
oncogenes. Mutations in these genes are common in breast cancer. They are found on chromosome 
17q21 and 13q12, respectively. Mutations in these genes leads to abnormal centrosome 
duplication, cell cycle checkpoint disruption, genetic instability and apoptosis. Mutations in these 
genes leading to breast cancer is closely related to heredity and the age factor (Chen S, 2007). 
Another oncogene found on chromosome 17 (17q12) called as human epidermal growth factor 
receptor 2 (HER2), also known as c-erbB-2, is closely related to breast cancer. It belongs to EGFR, 
tyrosine kinase family protein. Overexpression of this protein is observed in about 20% of the 
breast cancer patients (Davis NM, 2014). Epidermal growth factor receptor, located on cell surface 
stimulate many downstream pathways like, PI3K, Ras-Raf-MAPK and JNK, which are involved 
in stimulating cell proliferation, angiogenesis, migration etc. Overexpression of EGFR may lead 
to highly proliferative, metastatic tumor. More than 50% of the triple negative breast cancer 
patients (TNBC) have overexpression of EGFR (Kim A, 2017). Other than these mutations, there 
are many other mutations that are closely related to development of breast cancer. Several proteins, 
if overexpressed, may increase proliferation and metastasis in breast tumors, for example RNA 
helicase p68. Identifying those key players and the implicated pathways is required to develop new 
therapeutic regimes. 
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1.3.  Cell migration 
Cell migration is a crucial mainstay in the developmental process. Its role extends to a wide variety 
of physiological processes like embryogenesis, inflammatory response, and wound healing. Cell 
migration plays a key role in cancer advancement through metastasis. Migrating cells undergoing 
chemotaxis, the process of moving along with gradient of soluble chemoattractants and repellents, 
have an inherent navigation system that aids to sense said gradients and directs them to move. 
Migration toward or away from a chemotactic agent requires sensing directionality, polarity of the 
cell, and spatially coordinated movement. When a cell encounters an external gradient, it relays 
the appropriate signal to the cytoskeleton, component which modulates cell shape and motility. 
Cytoskeletal remodeling is majorly implemented by actin polymerization and proves to be the 
driving force behind orchestrated cell movement.  
Extracellular matrix (ECM) has a filamentous network with spaces between the fibers so that the 
cells can pass through. Some of the matrix polymers in tissues are collagen, laminin, elastin and 
other proteins and proteoglycans. ECM imposes steric hindrance on the migrating cells. Several 
factors govern the migration of a cell such as cytoskeletal prestress, stiffness of the ECM, adhesion 
and trans-cellular forces.  Transmission of said forces to neighboring cells occurs via cadherin-
type cell-cell adhesions. Normal liver tissue stiffness measured by magnetic resonance 
elastography at 90 Hz is 2 kPa while a cirrhotic liver 5kPa. Most of these studies show that some 
tumors e.g.: breast cancers exhibit increased tissue stiffness. Tumor cells can use tissue stiffness 
to their advantage by promoting tumor cell invasion, proliferation, and survival. 
Cell polarization precedes migration. There is a distinction of a leading front and rear in migrating 
cells, providing directionality to the pattern of migration. Polarity in epithelial cells is obtained 
through a signaling pathway involving Cdc42, Par3/6, and atypical protein kinase C that targets 
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microtubules. A polarized, migrating cell demonstrates asymmetric distribution of cytoskeletal 
elements as well as signaling components. High concentrations of actin were observed in the 
leading front while the rear exhibits elevated myosin concentrations. Phosphatidylinositol lipid 
(PIP3), phosphatidylinositol kinase (PI3K) are localized at the front while phosphatase and tensin 
homolog (PTEN) was displayed at the back.  
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1.4.  Helicases 
Proteins with several conserve motifs and the ability to move directionally along the nucleic acid 
strands are called as translocases. It is a big family of proteins and helicases are one of them. 
Nucleic acid dependent ATP-ases which can unwind the DNA or RNA duplex substrate are called 
as helicases. These helicases play role in different cellular processes which requires including 
DNA replication and repair, transcription, translation, ribosome synthesis, RNA maturation and 
splicing, and nuclear export processes. (Martin R. Singleton, 2007) 
The core structure of the helicases have a tandem RecA – like folds which causes protein 
conformational changes by converting chemical to mechanical energy by coupling NTP binding 
and hydrolysis (A.Rapoport, 2004). The characteristic feature of the core domain has conserve 
residues which are involved in binding and binding and hydrolysis of the NTP equivalent to the 
Walker A and B boxes of many ATPases (Gay, 1982) and an “arginine finger” that plays a key 
role in energy coupling (Klaus Scheffzek, 1997) 
Helicases have different biochemical properties, which help regulate their function in the cell. As 
DNA is a bipolar molecule, the proteins like helicases require directionality to transcribe the 
molecule correctly. Directionality is determined by polarity of the phosphodiester linkage in single 
stranded DNA. But in in double stranded DNA, the directionality is determined by the protein 
itself and the way it is loaded on the strand (Martin R. Singleton, 2007). The rate of translocation 
should be regulated in order to maintain the correct number of copies of DNA in the cell. The rate 
of the translocase is mainly maintained by the accessory proteins and also with the ATPase activity 
of the helicase. Helicases acts as catalyst to unwound the base pairs using free energy from ATP 
hydrolysis. For each ATP turnover how many base pairs are unwound describes the step size of 
the helicase. This step size is important for understand the efficiency of the helicase. 
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During 1993 helicases were classified in to two large families, super family 1 (SF1) and super 
family 2 (SF2),  based on their primary structure by Gorbalenya and Koonin. (V.Kooninbc, 1993). 
But not all helicases necessarily unwind the nucleic acid. They also act as motors by coupling NTP 
hydrolysis and direct the motion of the helicase along the nucleic acid. With the discovery of new 
domains and the functions of helicases, they are divided in to six super families. Helicases 
belonging to SF1/ SF2 have a single polypeptide chain with two RecA-like folds while other 
families have six or twelve rings of RecA-like folds. These families can be further subdivided as 
type A or Type B, based on the directionality of the translocation i.e. whether 3’-5’ or 5’-3’ (Martin 
R. Singleton, 2007).  
1.4.1.Super family 1 (SF1)  
Helicases belonging to SF1 family are subdivided in to SF1A and SF1B. Examples from SF1A 
family are the Rep and UvrD helicases in gram-negative bacteria and the PcrA helicase from gram 
positives. 
1.4.1.1 SF1A Helicases 
The structure of these family helicase comprises of a common fold, having two domains which 
further subdivided in to two subdomains. The cristal structure studies have shown that they have 
two RecA-like (N- and C-core) subdomains and the ATP- binding site lies in the cleft between 
these domains (Hosahalli S. Subramanya, 1996) (Waksman, 1997). These are flanked with many 
SF1 specific motiefs. Cristal structure of some proteins have also shown the single stranded DNA 
binding and different conformational changes (Waksman, 1997), confirming that these proteins 
involvement in the duplex unwinding. 
The helicase interacts with the single strand of the DNA which leads to conformational change in 
the form of rigid body movement, in one of the subdomain (2B) of the helicase and sets up a new 
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interface of subdomain 1B and 2B, facilitating its interaction with duplex DNA. ATP biding will 
further extend the conformational change in the cleft between the core motor domains 1A and 2A 
which leads to closing around the nucleotide. Once the cleft is closed, domains 1B and 2B forces 
the DNA duplex on to the negatively charged surface destabilizes the strand pairing. The cleft 
closer also leads to flipping of the bases in the single stranded region in to the pockets on the 
surface of the 1A and 2A domains. These movements all together translocate the helicase along 
the ssDNA. As core domain opens and closes, ATP binds, get hydrolyzed and then released 
(Martin R. Singleton, 2007).  
1.4.1.1 SF1B Helicases 
The helicases from SF1B family have two RecA-like core domains with an ATP-binding site 
between them, similar to the SF1A proteins, but there is also an additional N-terminal domain that 
forms the interface with the RecC subunit and they do not interact with duplex DNA ahead of the 
fork. 
1.4.2.Super Family 2 (SF2)  
This is the largest superfamily of helicases. Helicases from this family are involved in the wide 
variety of cellular processes. Few extensively studied subfamilies like DEAD-box RNA helicases 
(KyleTanneraPatrickLinder, 2006), the RecQ-like family (Richard J Bennett, 2010) and the Snf2-
like proteins belong to this family (panelAndrewFlausTomOwen-Hughes, 2004). One of the most 
important function of proteins belonging to this family is ATP-dependent directional translocation 
on single- or double-stranded nucleic acid. Some proteins also act as non processive mechanical 
switches, altering nucleic acid and nucleoprotein conformations in an NTP-dependent manner 
(Patrick Linder, 2006) (Martin R. Singleton, 2007). To understand the translocation of these 
helicases on the ss-DNA, structural analysis of the non structural protein 3 (NS3) of hepatitis C 
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virus belonging to SF2 helicase family was useful. These helicases unwind RNA and DNA 
duplexes using 3’ single stranded overhang (Pyle, 2002) (Tai CL1, 1996). In NS3 the C-terminal 
domain carries the protein –protein interaction while N-terminal domain acts as protease (Samuel 
G. Mackintosh‡, 2006).Two RecA- like proteins are present in core of the protein which forms a 
deep grove to accommodates helicase motifs which provide opportunity for nucleotide to bind and 
part of the ss-DNA binding site. When six bases of the ss-DNA bind to the core domain, it adapts 
open configuration. Because of the bases present in the pocket, the ss-DNA forms a pseudo B- 
form structure. This formation prevents the binding of another strand of the DNA. Residues from 
motifs 1a, TxGx, 4, and 5 gives contact site for nucleic acids with phosphodiester bond. The amino 
acids present at V432 and W501 site are called as bookend residue. They sandwich five bases 
across the core domain. The RecA– like domain provide additional DNA contact region 
surrounding the bookend residues. ATP hydrolysis cycle will alter the distance between bookends 
which causes opening and closing of the core domain. This movement along the contact with DNA, 
allows gripping and release of the DNA substrate and results in translocation of the protein and 
unwinding of the DNA (Martin R. Singleton, 2007). 
On the other hand, the DEA(D/H) box RNA helicases uses ATP-dependent conformational 
motions to produce localized RNA remodeling. To understand the translocation of SF2 family 
helicases on double stranded nucleic acid Rad54 helicase structure was studied. In order to start 
the translocation, and to be in open position, the C-core domain of the Rad54 undergoes the 
conformational change. The N-core domain recognizes both the DNA strands along the minor 
grove. Motifs 1a ns Snf2 maintain contact with phosphodiester backbone of the DNA keeping it 
in the B form conformation. One strand of the DNA duplex orients itself similar to the ssDNA in 
the N-core domain in the NS3 structure, to achieve the extensive protein: DNA contact. 
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1.4.2.1 DEAD-box family proteins 
Helicases having a conserved sequence of Asp-Glu-Ala-Asp (DEAD) residues are called as 
DEAD-box family helicases. These DEAD-box proteins belong to SF2 family of helicases. This 
is the largest subfamily in the SF2 helicase family. It is conserved from bacteria to humans 
(EFairman, 2007). They can bind to ssRNA, dsRNA or structured RNA. They have wide variety 
of functions in the cells, like RNA metabolism including transcription, splicing, transport, 
ribosome biogenesis, translation, RNA/protein complex assembly, and degradation (EFairman, 
2007) (Olivier Cordina, 2006) (Manuel Hilbert 1, 2009). Their main function is related to RNA as 
ATP- dependent chaperons that modifies RNA. Binding of the DEAD box helicases to RNA is 
ATP dependent. Instead of direct translocation, they work with RNA protein complexes (RNPs) 
and structured RNAs, alter RNA-protein interaction. (Manuel Hilbert 1, 2009). In order for ATP 
dependent RNA unwinding, these helicases bind to dsRNA and separate the strands apart without 
translocating on the nucleic acid.  
The structural studies of these helicases have shown the cleft between the two RecA-like domains 
having helicase motif.  They form the ATP and RNA binding sites. The specificity for ATP is 
provided by the Q motif contacting nucleotide base. The N-terminal RecA-like domainhave the I-
III motifs. C-terminal domain have IV-VI motifs (Martin R. Singleton, 2007). Without ATP and 
RNA two RecA-like domains do not interact and forms the open conformation (Ruairi Collins, 
2009). Upon binding with ssRNA, helicase kink the phosphate backbone, causing destabilization 
in the duplex, which leads to unwinding of the short duplexes. Here ATP binding is necessary for 
strand separation. Hydrolysis of ATP may not be required (Fei Liu, 2008). Helicase without ATP 
or ADP bound helicase will have low affinity toward RNA whereas ATP binding will increase the 
helicase affinity for RNA. Therefore when ATP is hydrolyzed RNA is released from the complex 
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(Olivier Cordina, 2006) (Herschlag, 1998). Kinetic parameters comparison for ATPase and 
unwinding reactions, study suggest that ATP binding increases the unwinding but hydrolysis of 
the ATP is not required. Therefore, ATP hydrolysis event may happen after dsRAN melting but 
before complete strand separation. Possibility of dissociation of the helicase from the strand is 
increased due to ATP hydrolysis, but the rate of unwinding is faster than dissociation rate. So ATP 
hydrolysis results in the strand separation. 
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1.5.  RNA helicase p68 
P68 RNA helicase (DDX5), prototypic member of the DEAD box family of RNA helicases (Lane 
and Hoeffler 1980), which, is crucial for the cell development, division, and organ maturation 
(Stevenson, Hamilton et al. 1998). RNA helicases belonging to DEAD box family contain 9 
domains of conserved peptide sequence. One of the major conserved sequence is Asp-Glu-Ala-
Asp (DEAD).  As the name suggest these proteins are mainly involved in recognizing RNA and 
RNA unwinding. Other than RNA unwinding, proteins belonging to this family are involved in 
plethora of activities like RNA like ribosome biogenesis, embryogenesis, spermatogenesis, and 
cell development and division etc. 
 
Figure 1.1 DDX5 domains 
p68 shares a "helicase core" of nine conserved motifs with other members of the DEAD-box 
family, and these conserved regions are critical for RNA binding, ATP binding and hydrolysis, 
and intermolecular interactions. The core is divided into two flexibly linked RecA-like domains, 
Domain 1(D1) and domain 2(D2). The D1, consisting of Q-motif, motifs I, II and III, serves for 
ATP-binding. The D2, including motifs IV, V and VI, exhibits an RNA-duplex recognition 
domain. The Q-motif is present at the N-terminus of the catalytic core and is preceded by a 
conserved phenylalanine 17 amino acids at the upstream This conserved aromatic group and the 
Q-motif are identified as adenine recognition motif and can regulate ATP binding and hydrolysis. 
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Further, the Q-motif was reported to affect the helicase activity through regulating the affinity 
between the protein with RNA.  Motifs I and II (or Walker A and B) are capable of binding ATP. 
The energy from ATP hydrolysis is coupled to RNA unwinding by motif III and cooperates with 
other motifs to create a high-affinity RNA binding site.  And motif IV, together with motif Ia, Ib 
and V, is engaged in ATP-dependent binding of RNA substrates.  Obviously, the structure of p68 
is in a dominant position in the representation of function, and there is a profound work which is 
remained to elucidate the mechanism between structure and biological activity 
Gene and Structure of p68 RNA Helicase 
Location of the human p68 RNA helicase is at chromosome 17q21 and encoded in DDX5 gene 
(Iggo et al 1989). Its cDNA sequence shows an open reading frame encoding a polypeptide of 614 
amino acids (Hloch et al 1990). The p68 RNA helicase was aciidentally discovered from its 
immunological cross-reaction with the anti-SV40 large T monoclonal antibody DL3C4 (PAb204) 
(Crawford et al 1982a, Lane and Hoeffler 1980a). As p68 is RNA helicase, it shows RNA 
helicases, ATP binding, RNA-dependent ATPase, activities in vitro (Hirling et al 1989, Iggo and 
Lane 1989b). 
Functions  
p68 is a multifunctional protein which can bind to both single stranded as well as double stranded 
RNA. With ATP hydrolysis it gives energy to unwind the RNA in bidirectional manner (Hirling 
H, 1989). It can arrange the spliceosome and efficiently carry out the RNA splicing (Hamm J, 
1998). But RNA helicase activity is not required for spliceosome arrangement (Lin C, 2005). It 
also plays an important role in RNA maturation, therefore it is safe to say that it has important 
function in alternative splicing (Guil S, 2003). P68 also plays role in microRNA (miRNA) 
biogenesis. Small non-coding RNA called as  micro RNA regulates protein synthesis by regulating 
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the mRNA (Ma R, 2012). Drosha and dicer are endonucleases which cleaves the mRNA to form 
primary miRNA (pri-miRNA) and precursor miRNA (pre-miRNA) respectively (Zeng Y, 2005) 
(Gregory RI, 2004). During this pri-miRNA to pre-miRNA transition, p68 recognize the pri-
miRNA and binds to specific structure (Fukuda T, 2007). P68 also acts as transcriptional co 
activator. For example, p68 interacts with estrogen receptor (ER), which is a nuclear receptor and 
regulates downstream genes of ER (Endoh et al 1999a). P68 is over expressed in almost all type 
of malignant tissues and cells, like colon cancer, prostate cancer, lung cancer, breast cancer etc. It 
has great impact on cancer cells proliferation and migration. It interacts with many different 
proteins which are involved in stimulating cell migration and proliferation. For example, β- 
catenin. The androgen receptor (AR) is also a nuclear receptor and act as transcription factor for 
more than 1200 genes. It has great deal of importance in breast cancer and prostrate cancer 
development and progression. (S. Wen, 2014). P68 is overexpressed in prostate and breast cancer. 
P68 siRNA knockdown resulted in to down regulation of AR responsive genes (Clark EL, 2008). 
So p68 also play major role in prostate and breast cancer development and progression via 
regulating the AR.	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1.6.  Platelet derived growth factors receptor (PDGFR)  
 
Figure 1.2 PDGFR family PDGF receptors and their ligands. 
Platelet derived growth factor receptors (PDGFR) belong to the family of tyrosine kinase family 
(Lemmon and Schlessinger 2010) they belong to class III type of (RTKs), It is a group of five 
members including PDGFRα and PDGFRβ, KIT, FMS and FLT3. Proteins belonging to PDGF 
family stimulates proliferation, survival, migration of the mesenchymal cells. 
PDGF receptors are found in two different types, α and β. Upon ligand binding they either form 
homodimer or heterodimer. There are 4 different types of ligands for these receptors PDGF A, 
PDGF B, PDGF C, PDGF D. PDGFRα can bind to PDGF A, B and C homodimer or PDGF AB 
heterodimer, while PDGFRβ can bind to PDGF B and D homodimers. The molecular size of the 
PDGFR α and β is approximately 170 -180 kDa. respectively. The human α-receptor gene is 
PDGFR αα 
homodimer
PDGFR ββ 
homodimer
PDGFR αβ 
heterodimer
AA AB CC BB DDLigands
Receptors
Extracellular
Intracellular
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localized on chromosome 4q12 (PaslierM.R.AltherrT.E.DormanD.T.Moir, 1994), and the β-
receptor gene is on chromosome 5 (Y. Yarden, 1986) 
Proteins from this family play important role in tissue homeostasis in adult and different 
developmental stages of embryo. If absent or malfunctioning at this stage, it can lead to a variety 
of developmental diseases. On the other hand, if it is overexpressed, it leads to malignancies or 
diseases involving excessive cell proliferation and migration. 
As PDGFR α and β exist in homodimeric and heterodimeric form with different combination of 
ligand molecule, they can transduce variety of cellular signals. These signals may have overlapping 
cellular outcome. Whereas signals and the output from the homodimers are more specific. For 
example, signal from both α and β homodimer can transduce mitogenic signal but their effect on 
the actin filament will differ.  Upon stimulation both can trigger los of stress fibers and plasma 
membrane ruffeling, but signal from PDGFR β mediates formation of circular actine structure on 
the dorsal surface of the cell (Claesson-­‐Welsh, 1992). Signal from PDGFR β stimulates 
chemotaxis, but PDGFRβ have opposite effect (A Siegbahn, 1990).  Both the receptors increase 
the cellular calcium concentration (DILIBERTO P. A., 1992). These growth factor signals result 
in anti apoptotic cellular signal by inhibition of the gap junctional communication between cells 
(Boynton, 1998) (R Yao, 1995).   
As ligand binds to the extracellular domain of the receptor, it induces dimerization of the receptors 
causing intracellular domains of the receptors to come close, resulting in asymmetric dimeric 
arrangement of the two kinase domains, leading to autophosphorylation in trans receptor units. 
This autophosphorylation event causes the conformational changes in the intracellular portion of 
the receptor, making catalytic sites exposed, resulting in activation of the kinases. These 
autophosphorylated tyrosine residues provide docking sites for different signal transduction 
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molecules having SH2 domain. Each receptor has about ten autophosphorylation sites. Each site 
provides docking site for molecules with different SH2 domains. For example, molecules having 
enzymatic activity like phospholipase C-y (PLCy), tyrosin kinase from Src, Fer families the 
GTPase activating protein (GAP) for Ras and the SHP-­‐2 tyrosine phosphatase (Westermark, 2017). 
This phosphorylated PDGFR binds to variety of signaling molecules like STAT family proteins. 
Once activated, they can act as transcription factors in a variety of cellular processes, some adaptor 
molecules. Adaptor molecules are the molecules which facilitate binding of multiple other proteins 
in order to relay the signal, for example phosphotidylinositol3’- kinase (PI3K), Grb2, Nck, Shc, 
Crk, GABA2 etc. Each protein relays the plethora of signaling events. regulatory subunit of PI3K 
acts as adaptor protein for catalytic subunit of p110 protein. Grb2 acts as adaptor protein for Sos1 
protein in order to relay the signaling through Ras- Erk1/2- MAP kinase pathway. Directly or 
indirectly, PDGF stimulation can further activate many pathways like JN, p38, small GTPases, 
Rac, Rho,CDC42 etc., which leads to cell survival, proliferation, and migration (panelJean-
BaptisteDemoulinAhmedEssaghir, 2014). This stimulation of different signaling molecule and 
involvement of wide variety of pathways, makes it difficult to pinpoint the link one particular 
pathway to specific response (Westermark, 2017). 
As PDGF stimulation regulates a variety of intracellular signaling, it is very important to keep this 
stimulation in check. One way to keep the the stimulation in control is internalization of the 
receptor. The internalization happens via clathrin coated pits into endosome after PDGF is bound 
to the receptor. pH in the endosome is very low and it can dissociate the receptor from its ligand, 
but until then relay of the signal continues. At this low pH, the dimerized receptor dissociates to 
form monomer and gets dephosphorylated (Yi Wang‡§, 2003).  
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Activated PDGFR signaling can be modulated depending on the different cellular environmental 
conditions or different protein complexes. Ras can be activated by PDGFR α and PDGFR β by 
docking on to Grb2/Sos1 complex. Ras –GAP complex can directly bind to PDGFR leading to 
inhibition of the activation of Ras but this complex cannot bind to PDGFRα. Therefore, PDGFRα 
activates Ras more efficiently than PDGFRβ (AleksandraJurekCarl-
HenrikHeldinJohanLennartsson, 2011) 
Involvement of PDGF in a variety of diseases 
PDGF stimulation plays important role at developmental stages, contributes to cell proliferation, 
migration and cell growth. But if overexpressed or over stimulated, it contributes to a lot of 
different diseases. It has been shown that mesenchymal cells express PDGF forming an autocrine 
loop, therefore when PDGF is overexpressed in these cells, it can be one of the reasons for fibrosis 
(CBonner, 2004). Overexpression of PDGF is observed in broncho alveolar fluid as well as tissues 
(CBonner, 2004). In kidney fibrosis, under glomerulosclerosis condition, PDGFR β stimulated by 
PDGF-BB or PDGF-CC seems to play role. But under interstitial fibrosis, PDGFR α stimulated 
by PDGF-AA or PDGF-CC plays a role (Tammo Ostendorf, 2011). This finding is supported by 
inhibition of PDGF signaling using PDGF neutralizing antibodies or treatment with imatinib, 
which is a PDGF inhibitor. These treatments reduced mesangial cell proliferation and matrix 
production in fibrotic kidneys in  animal models (R J Johnson, 1992) (Westermark, 2017). 
Chronic inflammation is observed in atherosclerotic lesions, under such condition immune cells in 
the area produces PDGF which acts on smooth muscle cells present in the vascular walls. This 
leads to proliferation of these cells and results in neointimal thickening (WRaines, 2004). In animal 
mouse models treatment with PDGFR β antibody, in which atherosclerosis was promoted via 
constitutively active PDGFR β showed promising results (GA Ferns, 1991). Overexpression of 
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PDGF is also observed in pulmonary artery hypertension, a serious condition. In this condition, 
pulmonary vasoconstriction and abnormal remodeling of small pulmonary resistance vessels and 
hyperplasia of smooth muscle cells is observed (Santosh S. Arcot, 1993). 
As PDGF signaling plays role in cell migration and proliferation, it is not difficult to imagine it 
would also have significant role in several types of human cancers. PDGF signaling tumor cells 
proliferation and migration but it also modulate tumor stroma to support tumor growth (Kristian 
Pietras, 2003). As mentioned above, PDGFR are expressed predominantly in mesenchymal cells, 
but when epithelial cells undergo epithelial to mesenchymal transition (EMT), in response to 
variety of signals e.g. Transforming growth factor β TGFβ, increased expression of PDGFR is 
observed (Aristidis Moustakas 1, 2016). Tumor cells arising from epithelial cells have undergone 
EMT, have overexpression of PDGFR. EMT changes stimulates increased production of PDGF. 
Thus these tumor cells can promote their survival and proliferation in autocrine manner 
(Westermark, 2017). It has been observed in the surgical specimen studies that, glioblastoma cells 
in human co-express PDGFR α and PDGF-AA. As PDGF-AA is a ligand for PDGFR α, it is safe 
to say that, PDGF –AA stimulates PDGFR α in autocrine manner in human glioblastoma 
(Hermanson M, 1992). The tissues which may develop in to sarcoma, generally express PDGFR. 
Biopsies of the soft tissue sarcoma, osteosarcomas and synovial sarcomas showed co-expression 
of the PDGFR and its ligand (Wang J, 1994) (Smits A, 1992) (Kubo T, 2008) (Ho AL, 2012) In 
majority of the prostrate cancer cells PDGFR β is overexpressed (Ko YJ, 2001). Moreover, 
expression of PDGFR β in the stromal area of prostate cancer correlates to clinical relapse (Yngve 
Nordby, 2017). In breast cancer studies, it has been observed that, breast cancer cells also express 
PDGF ligand isoforms and their receptors (Martin Jechlinger, 2006) and overexpression of 
PDGFRβ in stromal area leads to poor prognosis (hardwaj B) (Seymour L, 1993). Thus through 
21 
various studies and example it is evident that different isoforms of PDGF ligands and their 
receptors play significant role in development of variety of cancers and also their overexpression 
in the stromal area leads to decreased survival, relapse, and poor prognostics. 
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1.6.1.Platelet derived growth factor receptor beta (PDGFRβ) 
Platelet-derived growth factor receptor-beta (PDGFRβ) is a cell surface receptor tyrosine 
kinase (Wang, Wu et al. 2016). In order to translate the extracellular signal in biological form the 
PDGFRΒ has to bind to the ligand. PDGFRβ can bind to two types of ligands PDGF B or PDGF 
–D Andrae et al., 2008, Borkham-Kamphorst et al., 2015, Kondo et al., 2013) Upon PDGF BB 
binding  to PDGFRβ extracellular domain, PDGFRβ form dimer and through the cascade of 
downstream signaling the signal is translated in to biological form like cell migration, proliferation 
etc. (Shim et al., 2010). PDGFRβ play important role in development, tissue repair, wound healing 
etc. It also play a role in angiogenesis and collagen production.(Chen, Chen et al. 2013) 
Platelet derived growth factor receptor (PDGFRβ) is a receptor tyrosine kinase that is implicated 
in cell proliferation upon PDGF-BB stimulation (Betsholtz 2004, Jechlinger, Sommer et al. 2006). 
Substantial evidences indicate an increase in PDGFRβ- signaling in different stages of breast 
cancer and that it is highly upregulated in the human late stage mammary tumors. PDGFRβ-  
expression has also been correlated with an invasive phenotype in human breast cancer (Jechlinger, 
Sommer et al. 2006). It has been elucidated that an autocrine (platelet derived growth factor 
(PDGF-BB)/PDGFRβ loop is established in breast cancer cells through upregulation of both 
ligands and receptors, which leads to cell proliferation, migration, survival, and drug resistance 
(Guha 1991, Lokker, Sullivan et al. 2002, Yu, Ustach et al. 2003, Bonner 2004).  
 Nuclear localization of PDGFRβ upon PDGF-BB stimulation has recently been reported. 
Nuclear interaction of PDGFRβ controls cell proliferation by chromatin remodeling and regulation 
of p21 levels (Papadopoulos, Lennartsson et al. 2018). Also, nuclear PDGFRβ-  has been shown 
to control androgen receptor (AR) expression (Cuenca-Lopez, Montero et al. 2014, Papadopoulos, 
Lennartsson et al. 2018). Notably, AR overexpression is associated with breast cancer 
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aggressiveness (Moinfar, Okcu et al. 2003). It has also been reported that p68 RNA helicase is a 
coactivator of various steroid hormone receptors, including AR (Clark, Fuller-Pace et al. 2008). 
Clark et al. have previously demonstrated that p68 recruits AR and  -catenin to the promoter 
regions of androgen responsive genes, including prostate specific antigen resulting in increased 
AR transcriptional activity in prostate cancer (Clark, Hadjimichael et al. 2013). 
 Aberrant expression of p68 and PDGFRβ has been documented in three major human 
cancers, including breast (Seymour and Bezwoda 1994, Haines, Cajulis et al. 1996, Paulsson, 
Sjoblom et al. 2009, Hashemi, Masjedi et al. 2019), colon (Singh, Haines et al. 1995, Fujino, 
Miyoshi et al. 2018), and prostrate(Clark, Coulson et al. 2008, Nordby, Richardsen et al. 2017), 
suggesting the crucial role of both the proteins in tumorigenesis. Both p68 and PDGFRβ play an 
important role in cell proliferation and migration that are critical to cancer development. We have 
previously shown that p68 RNA helicase mediates PDGF-induced EMT by displacing axin from 
β-catenin (Yang, Lin et al. 2006). 
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1.7.  Androgen receptor (AR) 
 
Figure 1.3 Functional domains of the androgen receptor (AR): N-terminal domain, DNA binding 
domain (DBD), Ligand binding domain. (H – hinge region, NLS – nuclear localisation signal, NES 
– nuclear export signal) 
The androgen receptor is a transcription factor, belonging to steroid hormone receptor family. Few 
other notable examples of this family are, progesterone, estrogen, retinoic acid, thyroid, 
mineralocorticoid, vitamin D receptors (C. Chang, 1995) (C.S. Chang, Molecular cloning of 
human and rat complementary DNA encoding androgen receptors, 1988) (C.S. Chang, Structural 
analysis of complementary DNA and amino acid sequences of human and rat androgen receptors, 
1988). Androgen receptor binds to androgen and to mediate the physiologic effect of androgen. It 
binds to targeted DNA sequence and regulate its expression or suppression (Gelmann). 
Structure and regulation 
The single copy of androgen receptor gene is present on the chromosome Xq11.2-q12, oriented 
towards 5’end of the centromere. It spans around 90 kb of DNA (Gelmann). Eight exons comprise 
the coding sequence and approximately 2757 base pairs of open reading frame (Gelmann). The 
protein has 3 main domains as, Ligand binding domain (LBD), activation domain, and a DNA 
binding domain (DBD). Trans activation domain is transcriptional regulatory region present at N-
terminal domain (O. Sartor, 1999). Highly conserve DBD is encoded by second and third exon. It 
N-terminal domain DBD H LBD
C-terminalN-terminal
NLS NES
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is composed of two zinc finger domains. One deals with the receptor specificity for androgen 
response element (AREs) and the other one deals with receptor dimerization and binding with 
DNA. LBD is encoded by by exon 4-8. 12 helices form the ligand binding pocket and allows 
conformational changes upon ligand binding. A connecting region between LBD and DBD has a 
nuclear localization signal (Gelmann). Importin protein plays significant role in carrying AR into 
the nucleus. It binds to the NLS sequence of AR and carry it in to the nucleus. 
Chaparonin proteins like Hsp90, FKBP51, Hip, HSP70, p23 (J. Veldscholte, 1992), even 
cytoskeletal proteins (D.M. Ozanne, 2000), sequester inactive AR and keeps it in the cytoplasm. 
Once bound to its ligand, dihydrotestosterone (DHT), conformational changes will dissociate 
chaperonins from AR and it will be trans located to nucleus (Parth K.Modi, 2016). Proteins like 
the steroid receptor coactivator family (SRC/p160), cAMP response element binding protein 
(CREB) binding protein (CBP)/p300 and p300/CBP-associated factor (p/CAF), act as coactivator 
for AR. These proteins regulate histone modification, chromatin remodeling, 
chaperones, sumoylation, proteosomal degradation, and enhance AR transactivation (Z. Culig, 
2012) (Parth K.Modi, 2016). 
Few proteins inhibit the transcription initiation by AR, these are called as co-repressors. Few 
examples of co-repressor are the nuclear receptor corepressor (NCoR) and silencing mediator 
for retinoid and thyroid hormone receptors (SMRT). SMRT can recruit histone on the targeted 
DNA site and prevent binding of the AR by tightly packing the DNA. It also disrupt the N/C 
terminal interactionby interacting with NTD and LBD (G. Liao, 2003) 
Androgen receptor is susceptible to many modifications like, acetylation, phosphorylation, 
ubiquitination, sumoylation, or methylation after getting dissociated from the chaperons (M. Fu, 
2004) (S.A. Goueli, 1984) (K. Coffey, 2012). Proteins like receptor-tyrosine kinase (RTK) and G-
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protein coupled receptor (GPCR) signaling can activate AR through their downstream pathways, 
independent of the AR ligand (N.C. Bennett, 2010), (X. Cao, 2006). 
Functions 
As part of nuclear receptor family proteins, main function of AR is to serve as transcription factor. 
To perform this function AR has to bind to its ligands, which are, dihydrotestosterone (DHT), 
testosterone and its metabolites, estradiol and 5 - DHT (K. De Gendt, 2012). Different tisues 
respond to different stimulant. For example, for development in pubertal and prenatal period 
reproductive tissues respond to testosterone on the other hand, during development and 
maintenance of prostrate tissues DHT stimulation is preferred. Muscle tissues respond well to 
testosterone, whereas adipose tissues use estradiol, which is an aromatized form of testosterone 
(K. De Gendt, 2012).  
A study showed that AR can bind to over 1200 genes and actively regulate them (C.E. Massie, 
2011). These AR regulated genes are involved in cell cycle progression, metabolism, steroid 
biosynthesis etc. During early developmental stages, endodermal tissue from urogenital sinus and 
mesenchymal tissue surrounding it develop into rudimentary prostrate gland, in response to fetal 
androgens (G.R. Cunha, 2004). In adult presence of the AR in the prostatic epithelium helps 
maintain the controlled growth and inhibit the apoptosis. Many studies have also shown that AR 
signaling mediated interaction of prostatic stroma and epithelium plays a role in prostate cancer 
growth and progression (S. Wen, 2014). The circulating androgens are dehydroepiandrosterone-
sulfate (DHEAS), dehydro-androstenedione (DHEA), androstenedione (A4), testosterone, and 
DHT in women. DHEA, DHEAS, A4 are secreted by adrenal glands, while testosterone, DHEA 
and A4 are produced by ovaries. Testosterone, DHT and their metabolites are produced in 
peripheral tissues. These include brain, bone and breast. These circulating androgens at varied 
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concentration level are present in women, pre-menopausal or post-menopausal.  (Pia Giovannelli, 
2018). During mid-reproductive age in women, testosterone levels begin to decline while for post-
menopausal women, there is a decline in levels of androstenedione and DHEA. All these is mainly 
because of the reduced ovary functionality. This in turn decreases estrogen and progesterone 
production and no impact on testosterone levels. Correlating BC and circulating androgens, high 
levels of circulating androgens increase the probability of BC risks and is mainly found in pre-
menopausal women. However, there is no data to find a correlation between high level of other 
androgens and BC. For post-menopausal women, high levels of other androgens have higher BC 
risk impact.   
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CHAPTER 2 
2.  Materials and Methods 
2.1.  Cell Culture 
Breast cancer cell lines MDA MB 231, BT549, T47D, MCF 7, HCC1806, were purchased from 
ATCC. They were cultured and maintained in the recommended media at 37 °C with 0.5% CO2. 
Cells were stimulated with 1ηM PDGF BB. To see whether PDGFβ phosphorylation plays role in 
the pathway, 5 mM of protein tyrosine kinase inhibitor AG1296 (Cayman – cat # 146535-11-7) 
was used (specified in the figures).  
2.2.  Transfection 
To knock down p68, PDGFR β, in MDA MB 231 and BT549 cells, si RNA p68 (Santa cruz sc-
37141) or si RNA PDGFR β (ScBT- sc29442) respectively was transfected with 20–50 nM of 
siRNAs using Lipofectamine™ RNAiMAX Transfection Reagent kit from Thermo Fisher 
scientific. To overexpress PDGFRβ in MDA MB 231 and BT549 cells, 2.5 µg of PDGFRβ   
plasmid (Origene - RC206377) Lipofectamine™ 3000 Transfection Reagent kit from Thermo 
Fisher scientific was used. After 48 hr. incubation cells were used for further procedure.   
2.3.  DHT – MTT  
MDAMB 231, BT549 cells were either transfected with control siRNA or P68 siRNA, were treated 
with or without DHT 10 mM concentration for 24 hr. To analyze the cell proliferation these treated 
cells were incubated with Thiazolyl Blue Tetrazolium Bromide (MTT) (Millipore sigma Cat # 
M5655) for 4 hr at 370C. The absorbance was measured at λ 595 after dissolving the violate crystals 
in DMSO.  
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2.4.  Immunoblotting 
The proteins were analyzed by immunoblotting probed with p68 (ScBT sc-126730), 
PDGFRβ (Abclonal Cat # A2180) Phospho PDGFRβ SCBT Cat # Sc365465) Phospho EGFR 
(Abclonal Cat # Ab 40815), FGFR (ScBT sc- 390423), N-Cadherin (Invitrogen Cat # 33-3900), 
E-Cadherin (Biosciences Cat # 610404), Vimentin (Protein tech cat # 60330), Snail (Abcam cat # 
Ab 17732), AR (Agilent Cat # M356201), β-Actin (Bioscientific- R15006MC4) antibodies, 
according to the manufacturer’s instructions.   
2.5.  Scratch Assay  
MDA MB 231, BT549, cells were cultured into tissue culture plates and transfected with either 
Control, p68 si RNA or co- transfected with sip68 RNA and over expressed PDGFRβ for 48 hr in 
presence of 10 nM PDGF BB. Multiple scratches were introduced in the cultured plates. The 
scratch treated cells were directly visualized under the microscope.  
2.6.  Boyden chamber assay 
Permeable support, 24 well plate with 8.0 mm transparent PET membrane chambers were 
purchased from Life sciences and was used to measure the migration of MDA MB 231 and BT 
549 cells. The test cells were first transfected with either control si RNA or si p68 RNA (Santa 
cruz, Cat # sc-37141) for 48 hr. in regular cell culture plates. The treated cells were re-suspended 
into optimum medium (without serum) and seeded into the PET membrane chamber. The DMEM 
culture medium with 10% FBS was added to the outer chambers. After 12 hr incubation, medium 
in the inner chamber was removed and the cells attached to the outer bottom side were fixed with 
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room temperature paraformaldehyde and stained with 0.5% crystal violet. The stained cells were 
imaged under the inverted microscope.   
2.7.  Immunohistochemistry 
Deparaffinized, healthy breast and breast carcinoma sections were incubated in Lab Vision 
Hydrogen peroxide block and blocked with Lab Vision Protein block reagent. Tissue sections were 
incubated with rabbit monoclonal antibody against p68 (1:500 dilution) for 1 hour at room 
temperature. This was followed by detection with the Horseradish Peroxidase- 3,3′-
Diaminobenzidine (DAB) system. Nuclear counterstaining was done using hematoxylin. PDGFR 
β levels were quantified by staining intensity using imageJ software. 
2.8.  Immunofluorescence microscopy 
The MDA MB 231 and BT 549 cells were transfected or pretreated in the normal culture dish 
(treatments are specified in the figures). Once treatment was done, the cells were transferred on to 
poly lysine coated coverslips for overnight at 370C. After cells fixed in chilled 100% Acetone for 
15 min and blocked with 1% goat serum at room temperature for 1 hr. These cells were incubated 
with PDGFRβ antibody in a humidified chamber for overnight at 1:200 concentrations and then 
washed in PBS. Anti-rabbit secondary antibody conjugated with Alexa-555 was used to label 
PDGFRβ (1:2000 dilution). Nuclei were stained with Hoechst stain. Coverslips were mounted onto 
slides using Prolong-Gold antifade reagent (Invitrogen, Carlsbad). Images were taken with a 
fluorescence microscope (Keyence). 
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2.9.  Real time PCR 
RNA isolation was performed by generic Trizol-phenol chloroform protocol. The isolated RNA 
was quantified using Nanovue plus™ spectrophotometer (#28956057, Biochrom). cDNA was 
prepared using the Thermo scientific C-DNA kit. Real time PCR was performed using Luna 
Universal qPCR master mix (M3003L, NEB Inc) according to the manufacturer’s instructions. 
The primer sequences for DDX5 (F- GCCGACGTCAACGGGAAAGT, R- 
CGTTGTCACGTGGCTGTACC), PDGFR β (F- CCCCTTTCTGGCCTGATGCTC, R- 
TGATGTTCTCACCCTGGCGG), AR (F- GAAAGCGACTTCACCGCACC, R- 
AGGAATCCCTCTCTGCTCGC), Vimentin (F-TCCGCACATTCGAGCAAAGA, R- 
ATTCAAGTCTCAGCGGGCTC), N-cadherin (F-GCCAGAAAACTCCAGGGGAC, R-
TGGCCCAGTTACACGTATCC), Snail (F-GCTGCAGGACTCTAATCCAGA, R-
ATCTCCGGAGGTGGGATG), E- cadherin (F-TCATGAGTGTCCCCCGGTAT, R-
TCTTGAAGCGATTGCCCCAT), EGFR (F-GGCAGGAGTCATGGGAGAA, R-
GCGATGGACGGGATCTTAG), FGFR (F-ATGGCAACCTTGTCCCTG, R-
CAGCGCACCTCTAGCGAC), C-FOs (F- GTGTCCACCGCTGCCTTC, R- 
GCCACCATTGCTGAAGGGATT) were designed using NCBI Blast.  Quantitative PCR was 
done under the following thermocycler conditions: 95 °C for 2 min, and 40 cycles of 95 °C for 
30s, 62 °C for 1 min, and 95 °C for 30s. Data was collected from 7500 Fast Real-Time PCR System 
(Applied Biosystems) and analyzed using Excel. 
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2.10.  Statistical analysis 
To compare the two appropriate groups, the data sets were statistically analyzed. The P values 
were calculated using unpaired two-tailed Student’s t-test and anova test. In all figures and tables, 
NS means P>0.05 and statistically insignificant, *P<0.05, **P<0.01, and ***P<0.001. 
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CHAPTER 3 
3.  RNA helicase DDX5 regulates Platelet derived growth factor beta (PDGFRβ) expression 
3.1.  RNA helicase p68 is highly expressed in breast cancer 
RNA helicase p68 is a prototypic member of RNA helicase family having conserved DEAD box 
domain (Lane and Hoeffler 1980). Due to its RNA helicase, ATPase, and RNA unwinding activity, 
along with normal cellular functions like, pre-mRNA, rRNA, miRNA processing (Yang, Lin et al. 
2006, Yang, Lin et al. 2007, Fuller-Pace 2013), its role in cell division, organ development and 
maturation is well documented (Stevenson, Hamilton et al. 1998.  
Its high expression have been reported in colon caner (Singh, Haines et al. 1995) prostrate cancer 
(Clark, Coulson et al. 2008, Nordby, Richardsen et al. 2017) etc. To check its expression in breast 
tissue samples, breast carcinoma tissue array was purchased from US biomax (cat # Br1201). The 
specimens were studied using Immunohistochemistry technique. High expression of RNA helicase 
p68 was observed in breast carcinoma tissues as compared to healthy breast tissues.  
To gauge, if there is any impact of varying levels of p68 in breast cancer patients, the overall 
survival (OS) in breast cancer patients, was analyzed using publicly available data set (Nagy, 
Lanczky et al. 2018). To check the correlation between p68 expression in survival rate of patients, 
the overall survival probability of patients who expressed high p68 was compared with patients 
who expressed low p68 levels. The comparison clearly indicated the inverse correlation as, the 
high expression of p68 resulted in lower overall survival and lower expression of p68 results in 
higher overall survival in patients (Figure 3.1B). 
To check for the levels of p68 in breast carcinoma cell lines, we performed western blot analysis 
for p68 in T47D, MCF7, BT549, MDA-MB231, MDA-MB 468 and Hcc1806 cell lines. Strong 68 
KD band was observed in all the cell lines, indicating high levels of total p68 protein (Figure 3.1C).  
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Altogether, our results suggest that p68 plays a critical role in breast cancer progression. 
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Figure 3.1 p68 RNA helicase is associated with low overall survival in breast cancer. 
 (A) Tissue micro array was purchased from US biomax (cat # Br1201), immunohistochemistry 
staining of p68 in healthy breast and breast carcinoma tissues was performed. Strong 
expression of p68 was detected in breast carcinoma (right panel), as compared to healthy 
breast tissue (left panel). B. Overall survival probability in group of 1089 breast cancer 
patients. Note that higher expression of p68 (red line graph) corresponds to lower probability 
of overall survival, whereas low expression of the p68 (black line graph) correlates to higher 
overall patient survival in breast cancer. C, Western blot analysis shows the p68 protein levels 
in T47D, MCF7, BT549, MDA-MB 231, MDA-MB 468, HCC1806 breast carcinoma cell 
lines. 
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3.2.  RNA helicase p68 affects cell migration 
3.2.1. Effect of p68 knockdown through scratch assay  
Cancer cell migration is an important phenomenon in cancer metastasis. It has been observed that 
phosphorylated RNA helicase p68 through PDGF signaling promote β-catenin translocation to 
nucleus, to up regulate EMT genes, resulting in cell migration in colon carcinoma (Wang, Gao et 
al. 2013). To check whether p68 also plays role in breast cancer migration, p68 was knocked down 
in MDA-MB231 and BT549 cells using sip68 RNA. To compare the effect of p68 knockdown si 
control RNA treated MDA-MB231 and BT549 cells were used as control. Multiple scratches were 
introduced in the plates and the scratched area were observed for 24 hr. The relative percentage 
migration was calculated. In both the cell lines cell migration was reduced significantly.  
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Figure 3.2 Loss of RNA helicase p68 inhibits well migration 
(A)  RNA helicase p68 was knocked down using 2nM of sipi68 RNA in MDA-MB-231 and BT549. 
Scratch assay was performed to compare the cell migration within cells treated with control si 
RNA and cells treated with sip68 RNA. Scratch assay creates a wound or a gap in the growing 
confluent cell monolayer, following which a pattern of cell migration can be observed. 231 
and 549 cells migrate as loosely connected population. It was observed that the cells with down 
regulated expression of endogenous p68 show poor rate of migration as compared to control 
cells with normal p68 expression.  
(B)  Quantification of the relative migration was plotted. MDA-MB-231 cells were observed to 
show more significant effect on migration following p68 silencing compared to BT549 cells. 
The results represent findings of three independent experiments. Error bars represent mean ± 
S.E.M. **P<0.01, ****P<0.0001, ns denotes non-significant by unpaired Student’s t-test. 
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3.2.2. Cell invasion is affected upon 68 knockdown  
Another way of checking cell migration is using trans well chambers. In trans well chambers, cells 
are there are two chambers, inner and outer. These chambers are separated by a polyethylene 
terephthalate (PET) membrane with small pores (8 µm). Cells are seeded on the PET membrane 
in inner chambers with basic cell culture media and the chamber is placed in the outer chamber. 
The outer chamber has media with cell migration stimulation. 
To check whether p68 also plays role in breast cancer migration, p68 was knocked down in MDA-
MB231 and BT549 cells using sip68 RNA. To compare the effect of p68 knockdown si control 
RNA treaded MDA-MB231 and BT549 cells were used as control. These cells were re seeded in 
the inner chamber of trans well chamber with basic cell culture media. In the outer chamber, media 
with PDGF BB at 5 nM concentration was added as migration stimulation. The cells migrated in 
the outer chamber were stained with 0.5% crystal violate and observed under inverted microscope. 
The relative percentage migration was calculated. In both the cell lines, cell migration was reduced 
significantly after p68 knockdown.  
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Figure 3.3 Cell Migration upon p68 knock down. 
(A)  Cell migration assay was performed using transwel chambers, with set of breast cancer cells 
MDA-MB-231 and BT549 cells. This invasion assay analyzes rate of migration after exposure 
to a chemotactic agent. The invasive cells are stained using 0.5% crystal violate and counted 
with a light microscope under high magnification objective lens, with three individual fields 
per insert. It was observed that the p68 silenced MDA-MB-231 cells had low migration 
propensity compared to the control cells. A similar observation was made for the BT549 cells. 
This trans-well migration result points out that cells need expression of p68 for achieving 
optimum migration across a membrane.  
(B)  Quantification graph of the Boyden chamber assay was plotted depicting significant reduction 
in migration rate in cells treated with p68 siRNA. The results represent findings of three 
independent experiments. Error bars represent mean ± S.E.M. **P<0.01, ****P<0.0001, ns 
denotes non-significant by unpaired Student’s t-test. 
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3.2.3. P68 knockdown changes EMT marker profile 
Upon migration signal, stationary epithelial like cells trance-differentiate into mesenchymal like 
cells. Stationary cells loose their apical basal polarity, undergo a change in the signaling cascade 
and reorganize their cytoskeleton, that defines cell shape and reprograms gene expression. All 
these changes, prepare the cell for migration. These epithelial to mesenchymal (EMT) changes in 
the cells have significance in several biological processes like embryonic and post-embryonic 
development, tissue regeneration, wound healing, stem cell homeostasis, and in pathophysiology 
of fibrosis and malignancies. During EMT, cells express typical protein expression pattern. These 
proteins are called as EMT markers, which include high expression of Vimentin, N- cadherin, 
snail, decrease levels of E- cadherin expression etc.  
To validate p68 play role in EMT, P68 was knocked down using si p68 RNA in MDAMB231 and 
BT549 cells and mRNA levels were measured quantitative RT-PCR. Upon p68 knock down 
mRNA levels for vimentin, N-cadherin and snail went down significantly whereas expression of 
E-cadherin increase 3.5 folds. Same pattern could be seen through western blot analysis of protein 
expression of these proteins. Indicating p68 knockdown decreases migration and EMT in breast 
cancer cells upon PDGF-BB stimulation. 
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Figure 3.4 Changes in EMT markers after p68 knock down 
(A)  Real time PCR expression of mRNA was performed in the MDA-MB-231 and BT549 human 
breast cancer cell lines. The relative expression for classical Epithelial–mesenchymal transition 
markers such as vimentin, N-cadherin, SNAIL, E-cadherin were checked. The two conditions 
of the experiment were p68 siRNA treated cells and control cells.  
(B)  Western blot for the same markers was carried out in identical cell treatment conditions The 
results represent findings of three independent experiments. Error bars represent mean ± 
S.E.M. **P<0.01, ****P<0.0001, ns denotes non-significant by unpaired Student’s t-test. 
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3.3.  RNA helicase p68 regulates PDGFRβ  
Our results showed that knocking down of p68 decrease cell migration and invasiveness in the 
PDGF BB stimulated breast cancer cells. Upon ligand (PDGF-BB) binding platelet derived growth 
factor beta (PDGFRβ) promote cell migration (Yu, Moon et al. 2001) via Erk phosphorylation. 
Previous reports have shown PDGFRβ overexpression correlates with invasiveness of breast 
cancer (Jechlinger, Sommer et al. 2006). Therefore, the levels of phospho- PDGFRβ phospho 
Erk and Erk were explored in p68 knocked down MDA MB 231 and BT549 cells and compared 
with control MDA MB 231 and BT549 cells, in presence of PDGF BB stimulation. In p68 knocked 
down cells phospho- PDGFRβ and phosphor- Erk were down as compared to control cells. But 
Erk levels did not changed. Surprisingly, PDGFRβ levels were also significantly decreased in p68 
knocked down cells. 
To check whether knockdown of p68 also deplete other receptors tyrosine kinases (RTK) levels, 
protein levels of epithelial growth factor receptor (EGFR), which is a member of RTK family 
protein, were also checked, upon p68 knocked down. But protein levels of EGFR did not change 
when p68 was knocked down, as compared to control cells. Similarly, phosphor EGFR levels, 
were also stayed the same. This data clearly indicated that p68 regulates PDGFRβ levels in breast 
cancer cell line. 
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Figure 3.5 Effect of p68 knock down in PDGFRβ, EGFR, Erk and phospho- PDGFRβ , Phospho-
EGFR, phosphor Erk levels in MDA MB 231 and BT549 cells. 
 (A) Western blot analysis for p-PDGFRβ, p-PDGFRβ and pERK ½ (IB:ERK1/2), showed 
decreased levels of p-PDGFRβ and pERK upon p68 siRNA treatment as compared to control 
in MDA-MB231 cells. The levels for EGFR and p-EGFR did not show any change in their 
expression levels. But receptor PDGFRβ, levels wend down significantly in the p68 knocked 
down cells as compared to control cells.  
(B) The similar pattern of protein expression change was observed in BT549 cells as well.  
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3.3.1. RNA helicase p68 regulates PDFRβ but not other receptor tyrosine kinases (RTKs) 
As p68 was knockdown in breast cancer cells PDGFRβ levels also went down. To check whether 
this is true for other RTKs as well, western blot for EGFR and FGFR was analyzed. In both the 
cell lines, upon p68 knock down, only decrease in PDGFRβ protein levels were observed but 
EGFR and FGFR protein levels stayed the same.  
To check the mRNA levels upon p68 knock down, in these cells, RT PCR analysis for PDGFRβ, 
EGFR and FGFR was performed. The mRNA level change of EGFR and FGFR after p68 knock 
down was non significant. But on the other hand, the mRNA levels of PDGFRβ after p68 
knockdown were decreased by 10 folds confirming our finding that p68 regulates cell migration 
through PDGFRβ regulation.  
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Figure 3.6 Levels of receptor tyrosine kinases upon p68 knock down 
(A)  Western blotting for various growth factor receptors was carried out under the p68 siRNA 
treatment condition. The receptors checked were PDGFRβ, EGFR, FGFR. It was observed that 
the p68 knockdown results in lower PDGFRβ protein expression but there’s no change 
observed for the rest of the growth factor receptors. This implies that the p68 knockdown 
mediates the down regulation of PDGFRβ expression. 
(B)  Relative mRNA expression was measured by real time PCR for the same treatment conditions. 
The same trend was observed for the p68 knockdown treatment in which the PDGFRβ 
expression was lowered significantly 
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3.3.2. PDGFRβ overexpression rescues reduced cell migration after p68 knockdown 
Our data has shown that under PDGF BB stimulation, RNA helicase p68 promote cell migration 
in breast cancer cell lines and removing p68 from these cells will decrease the migration of these 
cells. Also PDGFRβ promote cell migration upon PDGF BB stimulation. But p68 knockdown will 
result in PDGFRβ depletion. So here we are hypothesizing that p68 affects cell migration by 
regulating PDGFRβ levels. In other words, overexpression of PDGFRβ after p68 knockdown 
should rescue the cell migration.  
So to check our hypothesis, p68 was knocked down in MDA MB 231 and BT549 cells, using sip68 
RNA. In one set of cells, PDGFRβ was overexpressed while p68 is knocked down. The wound 
healing assay was performed by introducing multiple scratches in the the dish. The cells were 
stimulated with 5 nM PDGF BB and were allowed to migrate in the wounded area for 24 hr. The 
fold change in cell migration was calculated by observing the scratches under the microscope and 
counting the migrated cells. The cell migration was reduced upon p68 knocked down as compared 
to the control cells. But when PDGFRβ was overexpressed while p68 was knocked down the cell 
migration came back to normal.  
This confirmed our hypothesis that p68 affects cell migration by regulating PDGFRβ levels. 
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Figure 3.7 Cell migration assay under p68 knockdown with or without PDGFRβ 
  overexpression 
(A)   This panel shows the scratch assay performed with cells treated under p68 
siRNA, p68 knockdown and PDGFRβ overexpression. The high migratory index was observed 
with control cells and cells treated with p68 siRNA and PDGFRβ overexpression. This 
indicates not p68 directly but presence of PDGFRβ in the cells is what facilitates the migratory 
signaling.  
(B)  Quantification of MDA-MB-231 cells under the above-mentioned treatment conditions.  
(C)  Quantification of BT549 cells under the same treatment conditions. 
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3.3.3.Cell morphology upon p68 knockdown and PDGFRβ over expression 
Upon migration signal, to prepare the cell for migration, cells undergo lot of morphological 
changes. For example, stationary cells loose their apical basal polarity, undergo a change in the 
signaling cascade and reorganize their cytoskeleton, that gives them typical spindle shape. On the 
other hand, when migratory or mesenchymal cells adopts epithelial nature they loose their spindle 
shape, starts to cluster together.  
MAD MB 231 cells are highly metastatic breast cancer cells. They are mesenchymal in nature, 
showing spindle shape fibroblast like morphology. But when p68 was knocked down they lost 
their elongated spindle shape and started to cluster together like epithelial cells. Indicating less 
migratory nature. But when PDGFRβ was over expressed when p68 was knocked down, cells still 
retained their elongated spindle shape. Cells were not clustered together, indicating their migratory 
nature. 
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Figure 3.8 Cell morphology of MDA MB 231 cells upon p68 knockdown with and without 
PDGFRβ overexpression. 
Cell morphology of MDA-MB-231 cells was observed under various treatments of control, p68 
knockdown by siRNA and silencing p68 and overexpression of PDGFRβ. The cells having p68 
knocked down showed more epithelial nature. They were lost their spindle shaped nature and 
clustered together. But cells PDGFRβ over expression maintained their mesenchymal nature even 
though p68 was knocked down. 
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3.3.4.Changes in EMT markers upon p68 knockdown and PDGFRβ overexpression  
Upon migration stimuli, stationary cells undergo epithelial to mesenchymal transition (EMT). 
These transition is result of cascade of signaling, which result in change in cell’s protein profile. 
In order to be motile cells need to increase express of proteins which support morphology change 
that enable the cell towards motile nature. Such changes include high expression of Vimentin, N- 
cadherin, snail, decrease levels of E- cadherin expression etc. which leads to loosing their apical 
basal polarity and achieving elongated spindle shape, mesenchymal nature. Where as when 
mesenchymal cells undergo mesenchymal to epithelial transition (MET) the reverse changes could 
be seen.  
To see the effect of p68 and PDGFRβ knockdown and PDGFRβ over expression with or without 
p68 knockdown, MDA MB 231 and BT549 cells, p68 was knocked down by transfecting 2nM si 
p68 RNA, PDGFRβ was knocked down using 2nM si PDGFR β RNA, with the help of RNA imax 
kit. PDGFRβ was overexpressed by transfecting PDGFR β plasmid, using Lipofectamine 3000 
kit. To knock down p68 and overexpressed PDGFRβ simultaneously co-transfection of si p68 
RNA and PDGFR β  plasmid was carried out.  
The wound healing assay was performed by introducing the multiple scratches in the plate. Cells 
were allowed to migrate under PDGF BB stimulation (5 µΜ) for 24 hr. After 24 hr. cells were 
observed under microscope and cell migration was analyzed by measuring the remaining size of 
the wound. When p68 and down PDGFR β were knocked down, cell migration went down by 2 
folds (Fig 3.9A 2nd and 3rd column), But when PDGFR β was overexpressed while p68 was 
knocked down (4th column), the cell migration fold change was comparable to the control cells, 
but it was significantly less as compared to the cells in which only PDGRβ was over expressed 
(5th column).  
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To check the EMT marker profile western blot analysis of snail, vimentin, E-cadherin was 
performed. When p68 and PDGFR β were knocked down, snail and vimentin protein levels went 
down significantly while E-cadherin levels increased (Fig 3.9 B, 3rd, 4th and 2nd line respectively, 
2nd and 5th column). Indicating epithelial nature increasing. When PDGFR β was overexpressed 
(Fig 3.9 B, 4th column), the snail and vimentin levels also increased (Fig 3.9 B, 3rd and 4th line). 
While E-cadherin went down (2nd line), indicating mesenchymal nature increasing. When 
PDGFRβ was overexpressed while p68 was knocked down (Fig 3.9 B, 3rd column), the snail and 
vimentin levels increased (Fig 3.9 B, 3rd and 4th line). While e-cadherin went down (2nd line), 
indicating mesenchymal nature restored by PDGFR β overexpression. The results were similar in 
the BT549 cells as well. 
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Figure 3.9 Effect of p68 knocked down can be restored by PDGFRβ overexpression 
(A)   Scratch assay was performed for MDA-MB-231 cells under p68 knockdown, PDGFRβ 
knockdown, PDGFRβ overexpression conditions. The cells with only overexpressed PDGFRβ 
show more migration than control cells. The cells with silenced p68 and double treatment of 
PDGFRβ siRNA and PDGFRβ overexpression have significantly lesser migration with respect 
to control cells.  
(B)  Western blot analysis for a panel of EMT markers in the same treatment conditions showed 
decreased snail and vimentin when p68 and PDGFRβ was knocked down, while E-cadherin 
went up. Increase in snail and vimentin was observed when PDGFRβ was overexpressed while 
E-cadherin went down. But wahe p68 was knocked down while PDGFRβ was over expressed, 
the expression of snail and vimentin increased and expression of E cadherin decreased. 
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3.3.5.PDGFRβ responsive genes get downregulated when p68 is knocked down 
PDGFRβ regulates cFOS expressing in breast cancer cells. c-Fos is involved in the signal 
transduction cascade of extracellular signals and regulation of transcription. In pathological 
conditions, c-Fos has been implicated in induction of epithelial-mesenchymal transition in cells 
which leads to metastatic growth in cancerous epithelial cells.  
Our observation showed that once p68 is knocked down, expression of PDGFRβ also goes down. 
Based on our hypothesis, p68 regulates PDGFRβ expressing upon PDGF BB stimulation. If p68 
is knocked down, then PDGFRβ responsive gene should also go down. 
To check this hypothesis, the levels of c-FOS, a PDGFRβ responsive gene were measured upon 
p68 knockdown. The mRNA levels of c-FOS were consistently decreased in MDAMB231 and 
BT549 cells upon p68 knockdown.  
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Figure 3.10 mRNA expression of PDGFR β	   responsive gene cFOS upon p68 knock down 
Relative mRNA expression of c-Fos was checked for MD-MB-231 BT549 cells. The p68 
knockdown cells have 2.5-fold lower c-Fos expression. 
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CHAPTER 4 
4.  RNA helicase DDX5 regulates androgen receptor (AR) expression  
Androgen receptor (AR) is widely expressed in breast cancer and is associated with poor prognosis 
(Moinfar, Okcu et al. 2003) Activation of AR through di hydrotestosterone (DHT) promotes cell 
proliferation in prostrate cancer cells and breast cancer cells (Hackenberg, Hofmann et al. 1988, 
Lin, Sun et al. 2009)  It has been shown that P68 RNA helicase acts as an AR transcriptional 
coactivator.  
Previous reports from our lab have shown that  p68 RNA helicase phosphorylation plays an 
important role in PDGF-BB induced cell proliferation via up regulation of cyclin D1 and c-Myc 
(Yang, Lin et al. 2007). And in our study, we noted that there was an increase in cell growth rate 
upon DHT treatment in PDGF-BB stimulated breast cancer cells. However, there was no effect on 
the cell growth rate upon DHT treatment in cells knocked-down with p68. Therefore, we sought 
to investigate whether p68 and PDGFR β co-regulate AR expression in breast cancer cells 
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4.1.  Upon RNA helicase p68 knockdown, Androgen receptor (AR) expression is down 
regulated 
As previously reported, AR promotes cell proliferation in breast cancer cells we tested 
proliferation in MDA MB 231 and BT 549 cells by stimulating DHT. DHT stimulated cells 
promote cell proliferation was observed. Our lab previously elucidated that p68 RNA helicase 
phosphorylation plays an important role in PDGF-BB induced cell proliferation via upregulation 
of cyclin D1 and c-Myc (Yang, Lin et al. 2007). So, to check if p68 knockdown have any effect 
on AR protein expression and mRNA levels, p68 was knocked down in in both MDA MB231 and 
BT549 cells using sip68 RNA under PDGF BB stimulation. The AR protein levels were compared 
using western blotting in presence or absence of p68. Surprisingly expression of AR was decreased 
under p68 knocked down condition as compared to the control (A). 
mRNA levels of AR were compared by RT PCR when p68 was knocked down vs control cells. 
The mRNA levels were decrease when p68 was knocked down (B). 
In our study, as we observed an increase in cell growth rate upon DHT treatment in PDGF-BB 
stimulated breast cancer cells. However, there was no effect on the cell growth rate upon DHT 
treatment in cells knocked-down with p68. To test this finding, we performed cell proliferation 
assay using a commercially available BrDU kit. BrDU assay demonstrated that proliferation in 
PDGF-BB stimulated MDAMB231 and BT549 cells significantly increased upon DHT treatment 
when compared to the control. However, cell proliferation was inhibited upon DHT treatment 
under p68 knockdown condition in both MDAMB231 and BT549 cells (C).  
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Figure 4.1 Androgen receptor (AR) in MDA-MB 231 and BT549 cells and effect of di hydro 
testosterone (DHT)  treatment on cell proliferation while p68 is knock down.  
(A) To check whether knock down of p68 affects androgen receptor protein levels, p68 was 
knocked down using 2 mM sip68 RNA from MDA-MB 231 and BT549 cells. Levels of p68 and 
androgen receptor were analyzed with western blot for AR showing Knocking down p68 resulted 
in reduced androgen receptor levels as well. The pattern is maintained in MDA-MB 231 and 
BT549 cells.  
(B)  To check whether p68 affects androgen receptors at Translational level or transcriptional level, 
relative mRNA levels of AR gene (AR mRAN: b Actin mRNA ratios) in MDA MB 231 and BT549 
cells were calculated by quantitative PCR. To compare 2mM sicontrol RNA was used as control. 
(C) Di hydro testosterone (DHT) is the stimulation for androgen receptor. Stimulating androgen 
receptors with DHT stimulates cell proliferation. So, percent change in cell proliferation, with or 
without DHT stimulation in with or without p68 knocked down was analyzed by MTT assay. In 
the control si RNA treated cells the cell proliferation increased significantly upon DHT treatment. 
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When p68 was knocked down, even with the DHT treatment the cell proliferation did not increase 
significantly. 
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4.2.  PDGFRβ regulates AR expression in breast cancer cells  
Our result suggested that upon p68 knockdown AR levels were decreased and therefore upon 
treatment with DHT, there was no effect on the cell proliferation. PDGFRβ has also been shown 
to control AR levels. Therefore, to further investigated AR expression upon PDGFRβ knockdown 
in breast cancer cells, PDGFRβ was knocked down using siPDGFRβ RNA. Intriguingly, 
significant reduction in the AR protein (A) and mRNA levels (B) was observed upon PDGFRβ 
knockdown, in both MDA MB 231 and BT549 cells. Similarly, cell proliferation was significantly 
inhibited in cells knocked-down with PDGFR β upon DHT treatment (C), suggesting that both 
p68 and PDGFRβ independently regulate AR expression in breast cancer cells. 
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Figure 4.2 . PDGFR β	  regulates AR expression and mediates the effect of DHT in proliferation of 
breast cancer cells 
(A)  Immunoblot analysis of AR in PDGF-BB stimulated MDAMB231 and BT549 cells upon 
PDGFRβ knockdown. Knockdown efficiency of PDGFRβ (IB: PDGFR β) was analyzed by 
immunoblot. β-actin (IB: β-actin) is the loading control. AR protein expression was 
significantly reduced upon PDGFRβ knockdown in both the cell lines.  
(B)  Relative mRNA levels of AR were measured using RT PCR, upon PDGFRβ knock down using 
2 nM of siPDGFRβ RNA. mRNA levels of AR were significantly reduced upon PDGFRβ   
knockdown in both the cell lines. 
(C)  Cell proliferation of MDAMB231 and BT549 cells with (open bar) or without (filled bar) DHT 
(1 nM for 24 h) upon PDGFRβ knock down were compared with the control. The cell 
proliferation, upon DHT treatment, in the PDGFRβ knocked down cells did not show 
significant difference. Whereas the cell proliferation, upon DHT treatment, in the control si 
RNA treaded cells, show significant increase. The experiments were performed in triplicate. 
Error bars represent mean ± S.E.M. **P<0.01, ***P<0.001, ns denotes non significant by 
unpaired Student’s t-test. 
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4.3.  AR expression is co regulated by RNA helicase p68 and PDGFRβ in breast cancer cell 
lines 
Since our Previous findings indicated that p68 regulates PDGFRβ expression, we sought to further 
investigate whether overexpression of PDGFRβ in p68 knocked-down cells would alter the levels 
of AR.  
Therefore, PDGFRβ was overexpressed in p68 knocked-down breast cancer cells. Interestingly, 
transient overexpression of PDGFRβ restored AR protein (A) and mRNA levels of AR (B) in 
breast cancer cells knocked-down with p68, suggesting that p68-PDGFRβ axis regulates AR 
expression. Cells transfected with control siRNA, PDGFRβ plasmid, and PDGFRβ siRNA were 
used as controls. Cell proliferation assay further corroborated our finding that overexpression of 
PDGFRβ in p68 knocked-down MDAMB231 and BT549 cells resulted in an increase in cell 
proliferation upon DHT treatment (Fig 4.3 C & D). Taken together, our data indicate that p68 and 
PDGFRβ co-regulate AR levels and mediate androgen dependent proliferation in breast cancer 
cells. 
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Figure 4.3 p68 regulates androgen receptor expression through PDGFRβ 
(A)  In MDA MB 231 and BT549 cells, p68 was knocked down by transfecting 2nM si p68 RNA, 
PDGFRβ was knocked down using 2nM si PDGFRβ RNA, with the help of RNA imax kit. 
PDGFRβ was overexpressed by transfecting PDGFRβ plasmid, using Lipofectamine 3000 kit. 
To knock down p68 and overexpressed PDGFRβ simultaneously co-transfection of si p68 
RNA and PDGFRβ plasmid was carried out. When p68 was knocked down PDGFRβ and AR 
protein levels went down significantly (A,1st and 3rd line, 2nd column).  When PDGFRβ was 
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overexpressed, the AR levels also increased (A,1st and 3rd line, 4th column). When PDGFRβ 
was knocked down, the AR levels decreased (A,1st and 3rd line, 5th column).. But when 
PDGFRβ was overexpressed while p68 was knocked down, the AR levels went back up (A,1st 
and 3rd line, 3rd column). The results were similar in the BT549 cells as well. 
(B)  To check whether p68 knockdown will affect the transcription of AR, RNA were isolated from 
MDA MB 231 and BT549 cells, in which either p68 or PDGFRβ was knocked down with 
sip68 or siPDGFRβ RNA or PDGFRβ was overexpressed by transfecting PDGFRβ plasmid, 
or p68 was knocked down and PDGFRβ was overexpressed simultaneously. In p68 and 
PDGFRΒ b knocked down cells AR mRNA levels went down significantly. In overexpressed 
PDGFRβ cells, AR levels increased significantly. While in the cells which had p68 knocked 
down and PDGFRβ overexpressed the mRNA of AR were comparable to control cells. 
(C)  & (D) Androgen receptor promotes cell proliferation upon Di hydro testosterone (DHT). To 
check how cell proliferation is affected after p68 knockdown, p68 was knocked down with 
sip68 or siPDGFRβ RNA or PDGFRβ was overexpressed by transfecting PDGFRβ plasmid, 
or p68 was knocked down and PDGFRΒ b was overexpressed simultaneously in MDA MB 
231 and BT549 cells. In the control cells as well as PDGFRβ overexpressed cells, cell 
proliferation was increased upon DHT treatment, while in p68 knocked down cells cell 
proliferation was not significant. This effect of p68 knocking down on cell proliferation could 
be successfully rescued by overexpressing the PDGFRβ. 
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4.4.  Nuclear PDGFRβ regulates AR expression in breast cancer cells. 
To evaluate the mechanism by which PDGFRβ regulates AR expression in breast cancer cells, we 
examined the levels of PDGFRβ in MDAMB231 cells upon PDGF-BB stimulation and compared 
them with the control. Upon PDGF-BB stimulation, we observed high PDGFRβ levels in the 
nucleus of the cells (A), which validates the observation by Papadopoulos et al. In their study, they 
demonstrated that PDGFRβ in response to PDGF-BB stimulation translocates to the nucleus and 
controls proliferation. In addition, PDGFRβ kinase activity is not essential for nuclear 
accumulation of PDGFRβ (Papadopoulos, Lennartsson et al. 2018). To further validate it, we 
examined PDGFRβ levels in the nucleus upon addition of phospho-PDGFRβ inhibitor, AG1296. 
In response to PDGF-BB stimulation, no change in the nuclear PDGFRβ levels were observed 
upon AG1296 treatment (A & B). Taken together, our results indicate that nuclear PDGFRβ 
regulates AR expression in breast cancer cells. 
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Figure 4.4 p68 regulates expression of  PDGFRβ but not the nuclear translocation. 
A)  Platelet derived growth factor, upon ligand stimulation goes in to the nucleus and act as 
transcription factor. When MDA-MB231 cells were stimulated with PDGF BB the PDGFRβ 
translocated in to the nucleus (top control panel). To check if phosphorylation of PDGFRβ is 
necessary for getting it translocated in the nucleus, cells were treated with PDGFRβ inhibitor 
AG1296 at 5 nM concentration for 24 hr. PDGF BB stimulated cells were compared to the 
cells which did not receive PDGF BB stimulation. It was observed that, even upon PDGF BB 
stimulation, PDGFRβ translocated to nucleus in the cells treated with AG1296.  
B)  The PDGFRβ translocation in the nucleus upon PDGF BB treatment under control vs 
PDGFRβ kinase inhibitor AG1296 was measured at different time point. In both the 
conditions, PDGFRβ translocation was highest at 30 min time point after PDGF BB 
stimulation.  
C)  In MDA MB 231 cells, PDGFRβ was knocked down (5th column), stimulated by PDGF BB 
10  M, (2nd and 3rd column), treaded with PDGFRβ inhibitor AG 1296 at 10 nM for 24 hr 
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(3rd and 4th column) and phosphor PDGFRβ, p68 AR levels were checked with 
immunoblotting. The phospo PDGFRβ and AR levels were increased as cells were 
stimulated by PDGF BB (Line 1, Column 2 and 3). In the cells treated with PDGFRβ   
phosphorylation inhibitor, phospho- PDGFRβ levels were decreased. But AR levels 
remained unchanged, indicating, phosphorylation of the PDGFRβ is not necessary for the 
regulation of the expression of AR (column 4) But when PDGFRβ was knocked down 
(column 5) both phosphor – PDGFRβ and AR levels went down. 
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CHAPTER 5 
5.  Discussion  
P68 RNA helicase aberrant expression is associated with recurrence free survival and breast cancer 
progression (Paulsson, Sjoblom et al. 2009). We have previously reported that p68 promotes cell 
migration and proliferation via Wnt/β−catenin signaling pathway (Yang, Lin et al. 2006). Nuclear 
β-catenin plays important role in Wnt signaling pathway, which can trigger cell proliferation, 
differentiation, and migration (Nelson and Nusse, 2004). Our previous report suggests that the 
cytoplasmic β−catenin can be translocated to nucleus via Wnt- independent  pathway(Yang, Lin 
et al. 2006). β-catenin is present in the cytoplasm in the complex of GSK-3β and Axin. Axin is an 
important protein factor that negatively regulates β-catenin nuclear translocation. It was shown 
that Axin acts as scaffolding protein for cytoplasmic β-catenin (Tolwinski and Wieschaus, 2004) 
In order to translocate cytoplasmic β-catenin in the nucleus, it has to be separated from the 
complex. Upon PDGF stimulation, C-abl kinase gets activated through src and trans located to 
nucleus, which in turn phosphorylates nuclear p68 (Yang, Lin et al. 2006). This phosphorylated 
p68 translocates to cytoplasm and binds with β -catenin. This interaction releases β -catenin from 
GSK 3 b. In order to release  β -catenin from axin, ATPase activity of p68 is necessary (Yang, Lin 
et al. 2006). β –catenin upregulates EMT markers in the nucleus. Thus p68 –PDGFRβ axis plays 
a very important role in EMT. 
In this study, we report that p68 regulates transcription of the growth factor receptor, PDGFRβ in 
response to PDGF-BB stimulation, and thereby enhances migration of breast cancer cells. Previous 
report from our lab demonstrated the role of p68 in mediating PDGF-BB induced EMT. Here, we 
further elucidate that PDGFRβ expression is in turn regulated by p68 to maintain a positive 
feedback loop in breast cancer cells. Our results indicate that p68 knock down decreases EMT, 
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however, transient overexpression of PDGFRβ in breast cancer cells with p68 knockdown restores 
migration.  
 The molecular mechanism by which ligand activation results in transcriptional repression 
of PDGFRβ is intriguing. P68 RNA helicase regulates the transcription of numerous genes, 
including Snail 1 (Carter, Lin et al. 2010), androgen receptor (AR) (Clark, Fuller-Pace et al. 2008). 
It has also been reported that p68 interacts with histone deacetylase 1, RNA polymerase II 
holoenzyme, and p300/CBP, suggesting its function in transcription (Nakajima, Uchida et al. 1997, 
Wilson, Bates et al. 2004). We speculate that p68 interacts with PDGFRβ and therefore regulates 
its transcription. Our future work will explore whether p68 directly interacts with PDGFR β or 
indirectly regulates its expression. In addition, the involvement of phosphorylated or 
unphosphorylated p68 RNA helicase in mediating transcriptional expression of PDGFRβ needs to 
be investigated. 
 P68 RNA helicase has been demonstrated as the co-activator of AR (Clark, Fuller-Pace et 
al. 2008), which is highly expressed in invasive breast cancer and prostate cancer. A recent report 
highlights the androgen-mediated invasiveness of triple negative breast cancer (TNBC) through 
AR/Src/PI3-K complex (Giovannelli, Di Donato et al. 2019). Androgen-induced proliferation via 
androgen receptor has also been well documented, which altogether leads to breast cancer 
progression. Additionally, PDGFRβ has been shown to control AR expression (Cuenca-Lopez, 
Montero et al. 2014). Because p68 decreases the levels of AR, we believe it would be interesting 
to investigate if the regulation of AR is through p68-PDGFRβ axis. Interestingly, transient 
overexpression of PDGFRβ in cells knocked-down with p68 restored AR expression levels. In 
addition, PDGFRβ knockdown also dramatically reduced the levels of AR. Our results clearly 
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demonstrate that AR is co-regulated by both p68 and PDGFRβ, which mediates androgen-induced 
proliferation in PDGF-BB stimulated breast cancer cells.  
 Recent evidence suggests that the nuclear translocation of PDGFRβ upon ligand 
stimulation controls proliferation. The PDGFRβ dimerizes in response to PDGF-BB stimuli and 
translocates in a clathrin-dependent like manner (Papadopoulos, Lennartsson et al. 2018). 
PDGFRβ regulation in the nucleus and the specific regulatory events it catalyzes that are important 
for modulation of gene transcription is uncharted territory. Here, in our study we show that nuclear 
translocation of PDGFRβ mediates transcriptional expression of AR. Because PDGFRβ kinase 
activity is not essential for the nuclear accumulation of PDGFRΒ- β (Papadopoulos, Lennartsson 
et al. 2018), we found that the addition of a kinase inhibitor had no effect on the AR expression 
levels. Taken together, our data suggests that p68-nuclear PDGFRβ axis regulates AR 
transcription.  
To our knowledge, this is the first report to determine the role of p68 in receptor tyrosine kinase 
expression and the role of PDGFRβ in AR expression, suggesting p68-PDGFRβ axis in AR 
regulation. PDGFRΒ- β and AR inhibition are considered to be one of the promising approaches 
for cancer therapy. However, both PDGFRβ and AR inhibitors have not been successful in the 
clinic so far. Deeper insights into the regulation of transcriptional activity of PDGFRβ through p68 
and AR through p68-PDGFRβ axis may help in therapeutic interventions. We believe this area is 
an important aspect for future exploration in light of dysregulated receptor tyrosine kinase and p68 
and AR overexpression in invasive breast cancer. 
PDGFRβ promotes EMT and cell migration in breast cancer cells. Nuclear interaction of PDGFRβ 
controls cell proliferation by chromatin remodeling (Papadopoulos, Lennartsson et al. 2018). P68 
RNA helicase has important role in tissue and organ developmental processes, including 
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embryogenesis (Seufert et al., 2000), early organ maturation (Stevenson et al., 1998), and wound 
healing (Kahlina et al., 2004). In our study we are reporting that, upon PDGF-BB treatment, p68 
regulate PDGFRβ transcriptionally. This finding reveals that nuclear p68 regulates PDGFRβ 
transcriptionally and thus EMT certainly provides a cellular and molecular basis for the 
developmental role(s) of the protein. 
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